Study to See if Liver and Spleen Elastography Can Predict Recurrence Risk of Liver Cancer After Radiofrequency Ablation

What this Trial Is About

Researchers are evaluating the relationship between liver and spleen stiffness, measured by elastography, and the risk of hepatocellular carcinoma HCC coming back after treatment with radiofrequency ablation RFA. This observational study also aims to explore whether these elastography values relate to overall survival, HCC-related survival, and risk of liver decompensation. Additionally, the study will assess connections between non-invasive biochemical tests and HCC recurrence risk in patients with chronic liver disease undergoing RFA. Participants are patients with chronic liver disease diagnosed with HCC who are candidates for RFA treatment. The study involves performing hepatic or splenic elastography using transient elastography Fibroscan or Acoustic Radiation Force Impulse ARFI methods. Participants will be followed to observe the association of these elastography measurements with clinical outcomes after RFA treatment. During the study, participants will undergo elastography procedures to measure liver and spleen stiffness and provide biochemical test samples. The main outcome measured is the association between elastography values and HCC recurrence risk over 12 months following RFA. Researchers will also monitor overall and HCC-related survival and liver function status. The study is observational, with no additional interventions beyond routine care, and participation involves regular assessments and follow-up over the study period.

Can Hepatic-splenic Elastography Predict the Risk of Hepatocellular Recurrence After Radiofrequency Ablation?